SCHEMBL22145183

SCHEMBL22145183

C/C=C\C(=C/C)C(=O)NCCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAAT5 Q96KN8 9/20 0.56
PLAAT4 Q9UL19 9/20 0.56
PLAAT3 P53816 8/20 0.56
PLAAT2 Q9NWW9 8/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
ALDH1A1 P00352 3/20 0.56
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
TAAR1 Q96RJ0 1/20 0.54
HPGD P15428 1/20 0.53
MMP1 P03956 1/20 0.51
POLB P06746 1/20 0.51
MMP2 P08253 1/20 0.51
MMP9 P14780 1/20 0.51
RECQL P46063 1/20 0.51
CA12 O43570 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19425688 0.86 PLAAT5 (0.49) PLAAT5PLAAT4PLAAT3PLAAT2SMN1; SMN2
SCHEMBL15184416 0.85 SMN1; SMN2 (0.55) PLAAT5PLAAT4PLAAT3PLAAT2SMN1; SMN2
SCHEMBL8321028 0.84 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1HPGDMMP1MMP2
SCHEMBL10843414 0.82 ALDH1A1 (0.73) SMN1; SMN2ALDH1A1NPC1RAB9ATAAR1
SCHEMBL10711293 0.82 ALDH1A1 (0.73) SMN1; SMN2ALDH1A1NPC1RAB9ATAAR1
SCHEMBL22412530 0.79 PLAAT5 (0.75) PLAAT5PLAAT4PLAAT3PLAAT2SMN1; SMN2
SCHEMBL25008046 0.79 SMN1; SMN2 (0.74) PLAAT5PLAAT4PLAAT3PLAAT2SMN1; SMN2
SCHEMBL10163215 0.76 SMN1; SMN2 (0.66) PLAAT5PLAAT4PLAAT3PLAAT2SMN1; SMN2
SCHEMBL4831685 0.76 PLAAT5 (0.70) PLAAT5PLAAT4PLAAT3PLAAT2SMN1; SMN2
SCHEMBL24799994 0.76 ALDH1A1 (0.52) PLAAT5PLAAT4PLAAT3PLAAT2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022125849-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2022-06-16 WO disclosed
US-11203582-B2 Benzamide derivatives for inhibiting endoplasmic reticulum (ER) stress THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) 2021-12-21 US disclosed
US-20200199094-A1 BENZAMIDE DERIVATIVES FOR INHIBITING ENDOPLASMIC RETICULUM (ER) STRESS THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA 2020-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200199094-A1 BENZAMIDE DERIVATIVES FOR INHIBITING ENDOPLASMIC RETICULUM (ER) STRESS HSPA5, TMBIM6, BAD PLAAT5 924/4885PLAAT4 689/4885PLAAT3 601/4885
US-11203582-B2 Benzamide derivatives for inhibiting endoplasmic reticulum (ER) stress HSPA5, TMBIM6, BAD PLAAT5 924/4885PLAAT4 689/4885PLAAT3 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.